This module is not currently running in 2024 to 2025.
A synopsis of the curriculum:
• Nanoparticles for drug delivery
• Polymers for drug delivery
• Vaccine delivery
Lectures (30 hours), Workshops (8 hours), MSCL (90 hours), Private Study (69 hours expected)
60% examination, 40% coursework and satisfactory attendance and performance at workshops.
C. Li and S. Wallace (2008) Polymer-drug conjugates: Recent development in clinical oncology, Advanced Drug Delivery Reviews, 60, 886–898
Merisko-Liversidge, E., Liversidge, G. and Cooper, E. (2003) Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur. J. Pharm. Sci., 18, 113 – 120.
Rieux, A., Fievez, V., et al. (2006) Nanoparticles as potential oral delivery systems for proteins and vaccines: A mechanistic approach J. Control. Release, 116, 1-27.
J.H. Parka et al (2008) Polymeric nanomedicine for cancer therapy, Progress in Polymer Science, 33, 113–137
J.R. Junutula et al (2008) Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index, Nature biotechnology, 26, 925-932
O.H. Brekke et al. (2003) Therapeutic antibodies for human diseases at the dawn of the twenty-first century, Nature Reviews Drug Discovery, 2, 52-62
A comprehensive understanding of the concepts that underpin advanced therapeutic agents and their delivery.
A critical awareness and understanding of current problems and/or new insights associated with pharmaceutical agents and their delivery.
The principles of medicine formulation and systems for medicine delivery in the body (PO8)
The properties of materials used for the delivery of biologically active molecules (PO7)
Biotechnology products and excipients; pharmaceutical application of the technologies of genomics and proteomics (PO6)
The actions of medicines within living systems: molecular; cellular; biological and physical aspects (PO17)
Absorption, distribution, metabolism and excretion (ADME) of medicines, including routes of administration, concepts and mathematical modelling (PO18)
The clinical evaluation of new medicines (PO22)
Medicine delivery devices, wound management products and other medical devices (including diagnostic agents and devices) (PO24)
University of Kent makes every effort to ensure that module information is accurate for the relevant academic session and to provide educational services as described. However, courses, services and other matters may be subject to change. Please read our full disclaimer.
